Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Pancreatic Cancer: early-phase trial registry
1 of 16 indexed Stage IV Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 1 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Stage IV Pancreatic Cancer: 16 US clinical trials tracked, 1 recruiting.
Stage IV Pancreatic Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition stage-iv-pancreatic-cancer
OPEN 1 | RECR 6% | LATE 1 | EARLY 15 | RANK #1060 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Recurrent Non-small Cell Lung Cancer (6% recruiting · 16 trials)
Stage IV Pancreatic Cancer lists 1 open slots (6% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Pancreatic Cancer is recruiting below its size-band peers.
1 of 16 indexed trials (6.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Pancreatic Cancer research.
National Cancer Institute (NCI) accounts for 7 of 16 trials (43.8%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 28 among the 16 trials that report a genuine target (sentinel values excluded). 14 of those (87.5%) plan for fewer than 100 participants.
-
Stage IV Pancreatic Cancer research is mostly interventional.
16 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT03682289
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
NCT03368963
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
University of Utah
NCT03825289
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00088894
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
National Cancer Institute (NCI)
NCT00085371
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer Research Team
NCT01488552
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00114244
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00075647
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
NCT01453153
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Edward Kim
NCT01924260
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Roswell Park Cancer Institute
NCT01497392
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Pancreatic Cancer Research Team
NCT01893801
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT00031694
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
National Cancer Institute (NCI)
NCT01232829
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT00331682
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
NCT02620865
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Pancreatic Cancer page
16 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IV Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage IV Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Pancreatic Cancer condition card totals 16 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.